These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3137685)

  • 1. Clearance of a novel recombinant tissue plasminogen activator in rabbits.
    Fu KP; Lee S; Hetzel N; Fenichel R; Hum HW; Speth J; Kalyan N; Hung PP
    Thromb Res; 1988 Jun; 50(5):679-85. PubMed ID: 3137685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of a novel recombinant tissue plasminogen activator, delta 2-89 TPA, in mice.
    Fu KP; Lee S; Hum WT; Kalyan N; Rappaport R; Hetzel N; Hung PP
    Thromb Res; 1988 Apr; 50(1):33-41. PubMed ID: 3135637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration.
    Lucore CL; Fujii S; Sobel BE
    Circulation; 1989 Jun; 79(6):1204-13. PubMed ID: 2498004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and characterization of positively charged tPA as a prodrug using heparin/protamine-based drug delivery system.
    Liang JF; Li YT; Connell ME; Yang VC
    AAPS PharmSci; 2000; 2(1):E7. PubMed ID: 11741223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion.
    Fong KL; Crysler CS; Mico BA; Boyle KE; Kopia GA; Kopaciewicz L; Lynn RK
    Drug Metab Dispos; 1988; 16(2):201-6. PubMed ID: 2898333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic properties of an Escherichia-coli-produced recombinant plasminogen activator (BM 06.022) in rabbits.
    Martin U; Fischer S; Kohnert U; Rudolph R; Sponer G; Stern A; Strein K
    Thromb Res; 1991 May; 62(3):137-46. PubMed ID: 1909815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
    Montoney M; Gardell SJ; Marder VJ
    Circulation; 1995 Mar; 91(5):1540-4. PubMed ID: 7867196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels.
    Chandler WL; Alessi MC; Aillaud MF; Henderson P; Vague P; Juhan-Vague I
    Circulation; 1997 Aug; 96(3):761-8. PubMed ID: 9264480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice.
    Lackowski NP; Pitzer JE; Tobias M; Van Rheen Z; Nayar R; Mosharaff M; Stringer KA
    Pulm Pharmacol Ther; 2010 Apr; 23(2):107-14. PubMed ID: 19879371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.
    Benedict CR; Refino CJ; Keyt BA; Pakala R; Paoni NF; Thomas GR; Bennett WF
    Circulation; 1995 Nov; 92(10):3032-40. PubMed ID: 7586274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.
    Emeis JJ; Verheijen JH
    Arzneimittelforschung; 1992 Mar; 42(3):358-62. PubMed ID: 1497699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor- and kringle 1-domains.
    Emeis JJ; Verheijen JH
    Ann N Y Acad Sci; 1992 Dec; 667():421-3. PubMed ID: 1309064
    [No Abstract]   [Full Text] [Related]  

  • 14. Can transcranial ultrasonication increase recanalization flow with tissue plasminogen activator?
    Ishibashi T; Akiyama M; Onoue H; Abe T; Furuhata H
    Stroke; 2002 May; 33(5):1399-404. PubMed ID: 11988621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul; 346(1):108-13. PubMed ID: 1407000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
    van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
    Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A faster-acting and more potent form of tissue plasminogen activator.
    Keyt BA; Paoni NF; Refino CJ; Berleau L; Nguyen H; Chow A; Lai J; Peña L; Pater C; Ogez J
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3670-4. PubMed ID: 8170967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers.
    Martin U; von Möllendorff E; Akpan W; Kientsch-Engel R; Kaufmann B; Neugebauer G
    Thromb Haemost; 1991 Nov; 66(5):569-74. PubMed ID: 1725068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction.
    Modi NB; Eppler S; Breed J; Cannon CP; Braunwald E; Love TW
    Thromb Haemost; 1998 Jan; 79(1):134-9. PubMed ID: 9459338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.